Autosomal dominant hypocalcemia type 1 (ADH1) is caused by gain-of-function mutations in the gene encoding the calcium-sensing receptor (
CASR),
1,2 a condition that results in hypocalcemia and seizures, hypomagnesemia, hyperphosphatemia, reduced parathyroid hormone (PTH) levels, and hypercalciuria. The receipt of calcium and vitamin D analogues for the treatment of ADH1 predisposes patients to nephrocalcinosis and renal impairment.
1,3 Calcium-sensing receptor antagonists, known as calcilytics, represent a possible treatment option
2 but are available only as a research tool and have not been approved for clinical use. However, recombinant PTH (1-34) (a peptide consisting of 34 N-terminal PTH amino acids) may increase the serum calcium level without causing hypercalciuria in patients with some forms of hypoparathyroidism.
4,5